Objective To investigate the efficacy and safety of decitabine + cytarabine + acclarithromycin + granulocyte colony stimulating factor(DCAG)regimen in the treatment of refractory recurrent lymphoid neoplasm.Methods A retrospective analysis was conducted on 6 patients with refractory relapsed lymphoid neoplasm in the department of hematology,Yan'an University Affiliated Hospital from January 2020 to December 2021,and to evaluate the curative effect.Results Among all the cases,4 cases were with B-acute lymphoblastic leukemia(B-ALL),1 case was with diffuse large B-cell lymphoma and 1 case was with peripheral T-cell lymphoma.After 1 course of induction chemotherapy,the overall response rate of the patients was 100％,and the adverse reactions were mainly the erythrocyte leukocyte and thrombocytopenia and corresponding complications that all patients in hematology department would appear after chemotherapy,which could be corrected by symptomatic treatment.Conclusion DCAG regimen is effective and safe in the treatment of refractory recurrent lymphoid neoplasm,but the number of the cases is small,and more clinical cases need to be collected.
DCAG regimenLymphoid neoplasmRefractory and recurrent
万方数据
维普
